Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

v3.22.0.1
Royalty and Commercial Payment Purchase Agreements - Aronora (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Agreements          
Long-term royalty and commercial payment receivables     $ 69,075 $ 34,575 $ 34,375
Contingent consideration under RPAs and CPPAs     8,075 75  
Impairment of long-term royalty receivable     0 $ 0  
Aronora | Royalty Purchase Agreement          
Agreements          
Number of drug candidates | item 5        
Non-royalties to be received (as a percent) 10.00%        
Future non-royalty payments to be received (as a percent) 5.00%        
Multiplier for cumulative amount of consideration paid | item 2        
Upfront payment $ 6,000        
Threshold amount of cumulative royalties on net sales per product 250,000        
Aggregate milestones payments per product 85,000        
Long-term royalty and commercial payment receivables 9,000        
Contingent consideration under RPAs and CPPAs 3,000        
Payments of contingent consideration   $ 3,000      
Impairment of long-term royalty receivable     $ 0    
Aronora | Royalty Purchase Agreement | SVB Loan          
Agreements          
Upfront payment $ 3,000        
Aronora | Royalty Purchase Agreement | Bayer Products          
Agreements          
Number of drug candidates | item 3        
Number of drug candidates subject to exclusive license option | item 1        
Royalties entity has right to receive (as a percent) 100.00%        
Non-royalties to be received (as a percent) 10.00%        
Contingent future cash payment for each product $ 1,000        
Potential future cash payments $ 3,000        
Aronora | Royalty Purchase Agreement | Non-Bayer Products          
Agreements          
Number of drug candidates | item 2        
Non-royalties to be received (as a percent) 10.00%